1. UnitedHealth's stock has fallen 56% in a year, yet insiders and institutional investors are increasing their stakes; 2. Despite disappointing Q2 earnings, new strategic guidance and cost-cutting measures may signal a potential recovery; 3. The author's bearish valuation still projects nearly 30% upside potential for UNH.
Related Articles
- Verizon Communications Remains A Compelling Value Playabout 1 month ago
- S&P 500 Earnings: Nothing Much This Week, But Don't Ignore Non-Correlatedabout 1 month ago
- Nvidia Q1 Earnings Review: China Restrictions Getting Worse3 months ago
- Okta Earnings: Growth Slows, But Financial Strength Stands Out3 months ago
- Nvidia: Roaring Into Q1 Earnings Release After Unjustified Pullback3 months ago
- Palantir: How I'm Betting On Its Continued Explosive U.S. Commercial Growth3 months ago
- ConocoPhillips: Just Too Many Headwinds3 months ago
- Altria FQ1: Total Shareholder Yield Exceeds 10%4 months ago
- BHP Group: Long-Standing Preference For Rio Tinto, Neutral Rating Confirmed6 months ago
- Alphabet: Why The Google Cloud Selloff Has A Silver Lining (Rating Upgrade)6 months ago